BioCentury | May 25, 2018
Financial News

Consonance, Jay Mohr partner to invest in deprioritized therapeutics

Through a collaboration with biotech executive Jay Mohr, Consonance Capital Partners (New York, N.Y.) plans to make its first therapeutics investments out of its $500 million private equity fund, with the aim of increasing the...
BioCentury | May 22, 2018
Financial News

Consonance, Jay Mohr partner to invest in deprioritized therapeutics

Through a collaboration with biotech executive Jay Mohr, Consonance Capital Partners plans to make its first therapeutics investments out of its $500 million private equity fund, with the aim of increasing the profitability of deprioritized...
BioCentury | Jun 18, 2007
Tools & Techniques

Nuvelo's stealth target

Ever since Nuvelo Inc. was formed through the merger of Hyseq Pharmaceuticals Inc. and Variagenics Inc. in 2003, the company's clinical focus has been on compounds in-licensed from third parties. Although it's been relatively silent...
BioCentury | Mar 27, 2006
Finance

Ebb & Flow

BioMarin (BMRN; SWX:BMRN) last week tapped the debt and equity markets to the tune of $267 million in a follow-on and senior subordinated note deal. The financings punctuate the end of BMRN's pediatric detour, and...
BioCentury | Sep 6, 2004
Strategy

Asset accumulation

A few months ago, BioCentury spilled a lot of ink to deconstruct the NRDO model of no-research, development only companies being formed to scavenge for products or technologies that can be commercialized quickly and offer...
BioCentury | Apr 19, 2004
Company News

Gloucester management update

Gloucester Pharmaceuticals Inc. , Cambridge, Mass. Business: Cancer Hired: Joseph Mohr as president, CEO and a director, formerly president and CBO Variagenics Inc. WIR Staff cancer...
BioCentury | Apr 13, 2004
Company News

Gloucester names Mohr CEO

Gloucester (Cambridge, Mass.) hired Joseph Mohr as president, CEO and a director. Mohr previously was president and CBO of Variagenics , which merged with Hyseq to become Nuvelo (NUVO). Gloucester , which was founded in 2003, is...
BioCentury | Mar 1, 2004
Strategy

Pharmacogenomics deals

Pharmacogenomics deals PG provider Partner Focus Deal Value Year deCode Vertex Autoimmune DCGN's Encode CRO subsidiary to gather and analyze PG data for VRTX compounds in clinical trials run by Encode, starting with ongoing Icelandic...
BioCentury | Jan 5, 2004
Company News

NaPro management update

NaPro BioTherapeutics Inc. (NPRO), Boulder, Colo. Business: Cancer Hired: Anne Bailey as VP of diagnostics and reagents and general manager of NPRO's genomics division, formerly VP of diagnostics at Variagenics Inc. WIR Staff cancer Diagnostic...
BioCentury | Oct 2, 2003
Financial News

Nuvelo raises $24.5 million

NUVO raised $24.5 million in a private placement of 10 million shares at $2.45. JMP Securities served as the underwriter. NUVO's alfimeprase thrombolytic is in Phase II testing to treat peripheral arterial occlusion. The compound...
Items per page:
1 - 10 of 106
BioCentury | May 25, 2018
Financial News

Consonance, Jay Mohr partner to invest in deprioritized therapeutics

Through a collaboration with biotech executive Jay Mohr, Consonance Capital Partners (New York, N.Y.) plans to make its first therapeutics investments out of its $500 million private equity fund, with the aim of increasing the...
BioCentury | May 22, 2018
Financial News

Consonance, Jay Mohr partner to invest in deprioritized therapeutics

Through a collaboration with biotech executive Jay Mohr, Consonance Capital Partners plans to make its first therapeutics investments out of its $500 million private equity fund, with the aim of increasing the profitability of deprioritized...
BioCentury | Jun 18, 2007
Tools & Techniques

Nuvelo's stealth target

Ever since Nuvelo Inc. was formed through the merger of Hyseq Pharmaceuticals Inc. and Variagenics Inc. in 2003, the company's clinical focus has been on compounds in-licensed from third parties. Although it's been relatively silent...
BioCentury | Mar 27, 2006
Finance

Ebb & Flow

BioMarin (BMRN; SWX:BMRN) last week tapped the debt and equity markets to the tune of $267 million in a follow-on and senior subordinated note deal. The financings punctuate the end of BMRN's pediatric detour, and...
BioCentury | Sep 6, 2004
Strategy

Asset accumulation

A few months ago, BioCentury spilled a lot of ink to deconstruct the NRDO model of no-research, development only companies being formed to scavenge for products or technologies that can be commercialized quickly and offer...
BioCentury | Apr 19, 2004
Company News

Gloucester management update

Gloucester Pharmaceuticals Inc. , Cambridge, Mass. Business: Cancer Hired: Joseph Mohr as president, CEO and a director, formerly president and CBO Variagenics Inc. WIR Staff cancer...
BioCentury | Apr 13, 2004
Company News

Gloucester names Mohr CEO

Gloucester (Cambridge, Mass.) hired Joseph Mohr as president, CEO and a director. Mohr previously was president and CBO of Variagenics , which merged with Hyseq to become Nuvelo (NUVO). Gloucester , which was founded in 2003, is...
BioCentury | Mar 1, 2004
Strategy

Pharmacogenomics deals

Pharmacogenomics deals PG provider Partner Focus Deal Value Year deCode Vertex Autoimmune DCGN's Encode CRO subsidiary to gather and analyze PG data for VRTX compounds in clinical trials run by Encode, starting with ongoing Icelandic...
BioCentury | Jan 5, 2004
Company News

NaPro management update

NaPro BioTherapeutics Inc. (NPRO), Boulder, Colo. Business: Cancer Hired: Anne Bailey as VP of diagnostics and reagents and general manager of NPRO's genomics division, formerly VP of diagnostics at Variagenics Inc. WIR Staff cancer Diagnostic...
BioCentury | Oct 2, 2003
Financial News

Nuvelo raises $24.5 million

NUVO raised $24.5 million in a private placement of 10 million shares at $2.45. JMP Securities served as the underwriter. NUVO's alfimeprase thrombolytic is in Phase II testing to treat peripheral arterial occlusion. The compound...
Items per page:
1 - 10 of 106